Infliximab biosimilar (Shanghai CP Guojian)

英夫利西单抗生物类似药（三生国健药业(上海)）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Shanghai CP Guojian)
Drug Alias Name英夫利西单抗生物仿制药（三生国健药业(上海)）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeL04AB02
Related LinksN/A